Chief People Officer, Amy Hanlon-Rodemich to leave Nokia

Nokia Corporation
Stock Exchange Release
28 March 2024 at 16:15 EET

Chief People Officer, Amy Hanlon-Rodemich to leave Nokia

Espoo, Finland – Nokia today announces that its Chief People Officer, Amy Hanlon-Rodemich, will leave the company and step down from its Group Leadership Team. A recruitment process will begin immediately for her successor and Amy will retain an advisory role during her notice period.

Amy joined Nokia in 2022 and has been key to renewing the company’s people services and employee experience.

“This has been a difficult decision for me to take. I’ve enjoyed my time at Nokia and am looking forward to the next chapter in my career. I wish everyone at Nokia continued success,” commented Amy.

“I would like to thank Amy for her contributions to Nokia and leadership of the People organisation. I wish her all the best with her future endeavours,” said Pekka Lundmark, President and CEO of Nokia.

Lorna Gibb, Vice President, Labor & Employment, will assume the role of interim Chief People Officer for Nokia as the search commences.

About Nokia
At Nokia, we create technology that helps the world act together.

As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs.

Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks today – and work with us to create the digital services and applications of the future.

Inquiries:

Nokia Communications
Phone: +358 10 448 4900
Email: [email protected]
Kaisa Antikainen, Communications Manager

Nokia
Investor Relations
Phone: +358 40 803 4080
Email: [email protected]

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
• La Paz Moves at a Different Pace — Adventure Beyond the Shore
• Top Meme Coins 2026: DOGE, SHIB and PENGU Are Listed, but IceBull Is the Stage 1 Buy Before the Crowd